<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: financial condition", fill: "#cc4e5c"},
{source: "2: financial condition", target: "2: cash flows could", fill: "#cc4e5c"},
{source: "2: cash flows could", target: "2: materially adversely effected", fill: "#cc4e5c"},
{source: "2: financial condition", target: "5: THE COMPANY ", fill: "#ffcba4"},
{source: "5: THE COMPANY ", target: "5: previously", fill: "#ffcba4"},
{source: "5: THE COMPANY ", target: "8: thousands except", fill: "#50c878"},
{source: "8: thousands except", target: "8: presently unable", fill: "#50c878"},
{source: "8: presently unable", target: "8: particular strategic", fill: "#50c878"},
{source: "8: particular strategic", target: "8: alternative will", fill: "#50c878"},
{source: "8: alternative will", target: "8: consideration", fill: "#50c878"},
{source: "8: consideration", target: "8: implementation", fill: "#50c878"},
{source: "8: implementation", target: "8: strategic alternatives may", fill: "#50c878"},
{source: "8: thousands except", target: "9: Uncertainties ", fill: "#177245"},
{source: "9: Uncertainties ", target: "9: consideration", fill: "#177245"},
{source: "9: consideration", target: "9: alternatives", fill: "#177245"},
{source: "9: alternatives", target: "9: operations", fill: "#177245"},
{source: "9: operations", target: "9: management", fill: "#177245"},
{source: "9: management", target: "9: employees which", fill: "#177245"},
{source: "9: employees which", target: "9: could adversely affect", fill: "#177245"},
{source: "9: could adversely affect", target: "9: exploring strategic alternatives may", fill: "#177245"},
{source: "9: exploring strategic alternatives may", target: "9: expensive than currently", fill: "#177245"},
{source: "9: expensive than currently", target: "9: successfully", fill: "#177245"},
{source: "9: successfully", target: "9: alternative undertaken", fill: "#177245"},
{source: "9: alternative undertaken", target: "9: uncertainties as", fill: "#177245"},
{source: "9: uncertainties as", target: "9: future direction", fill: "#177245"},
{source: "9: future direction", target: "9: and other Company ", fill: "#177245"},
{source: "9: and other Company ", target: "9: employees customers clients", fill: "#177245"},
{source: "9: Uncertainties ", target: "13: businesses", fill: "#b38b6d"},
{source: "13: businesses", target: "13: significant", fill: "#b38b6d"},
{source: "13: significant", target: "13: transaction", fill: "#b38b6d"},
{source: "13: transaction", target: "13: previously", fill: "#b38b6d"},
{source: "13: previously", target: "13: development", fill: "#b38b6d"},
{source: "13: businesses", target: "14: financial printing costs severance", fill: "#007fbf"},
{source: "14: financial printing costs severance", target: "14: closure costs associated with", fill: "#007fbf"},
{source: "14: closure costs associated with", target: "14: elimination", fill: "#007fbf"},
{source: "14: elimination", target: "14: discontinued products employees operations", fill: "#007fbf"},
{source: "14: discontinued products employees operations", target: "14: facilities", fill: "#007fbf"},
{source: "14: financial printing costs severance", target: "START_HERE", fill: "#007fbf"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Oil and Gas Storage and Transportation</td>
    </tr>
    <tr>
      <td>Oil and Gas Refining and Marketing and Transportation</td>
    </tr>
    <tr>
      <td>Transportation</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_condition_report">Financial condition report</a></td>
      <td>In accounting, a financial condition report (FCR) is a report on the solvency condition of an insurance company that takes into account both the current financial status, as reflected in the balance sheet, and an assessment of the ability of the company to survive future risk scenarios. Risk assessment in an FCR involves dynamic solvency testing, a type of dynamic financial analysis that simulates management response to risk scenarios, to test whether a company could remain solvent in the face of deteriorating economic conditions or major disasters.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Balance_sheet">Balance sheet</a></td>
      <td>In financial accounting, a balance sheet (also known as statement of financial position or statement of financial condition) is a summary of the financial balances of an individual or organization, whether it be a sole proprietorship, a business partnership, a corporation, private limited company or other organization such as government or not-for-profit entity. Assets, liabilities and ownership equity are listed as of a specific date, such as the end of its financial year.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_statement">Financial statement</a></td>
      <td>Financial statements (or financial reports) are formal records of the financial activities and position of a business, person, or other entity.\nRelevant financial information is presented in a structured manner and in a form which is easy to understand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_ratio">Financial ratio</a></td>
      <td>A financial ratio or accounting ratio is a relative magnitude of two selected numerical values taken from an enterprise's financial statements. Often used in accounting, there are many standard ratios used to try to evaluate the overall financial condition of a corporation or other organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Trustmark_(bank)">Trustmark (bank)</a></td>
      <td>Trustmark is a commercial bank and financial services company headquartered in Jackson, Mississippi, United States, with subsidiaries Trustmark National Bank, Trustmark Investment Advisors, and Fisher Brown Bottrell Insurance. The bank's initial predecessor, The Jackson Bank, was chartered by the State of Mississippi in 1889.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_analysis">Financial analysis</a></td>
      <td>Financial analysis (also referred to as financial statement analysis or accounting analysis or Analysis of finance) refers to an assessment of the viability, stability, and profitability of a business, sub-business or project. \nIt is performed by professionals who prepare reports using ratios and other techniques, that make use of information taken from financial statements and other reports.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Form_10-K">Form 10-K</a></td>
      <td>A Form 10-K is an annual report required by the U.S. Securities and Exchange Commission (SEC), that gives a comprehensive summary of a company's financial performance. Although similarly named, the annual report on Form 10-K is distinct from the often glossy "annual report to shareholders," which a company must send to its shareholders when it holds an annual meeting to elect directors (though some companies combine the annual report and the 10-K into one document).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Company">Company</a></td>
      <td>A company, abbreviated as co., is a legal entity representing an association of people, whether natural, legal or a mixture of both, with a specific objective. Company members share a common purpose and unite to achieve specific, declared goals.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Walt_Disney_Company">The Walt Disney Company</a></td>
      <td>The Walt Disney Company, commonly known as Disney (), is an American multinational mass media and entertainment conglomerate headquartered at the Walt Disney Studios complex in Burbank, California.\nDisney was originally founded on October 16, 1923, by brothers Walt and Roy O. Disney as the Disney Brothers Cartoon Studio; it also operated under the names the Walt Disney Studio and Walt Disney Productions before changing its name to the Walt Disney Company in 1986.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Holding_company">Holding company</a></td>
      <td>A holding company is a company whose primary business is holding a controlling interest in the securities of other companies. A holding company usually does not produce goods or services itself.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/East_India_Company">East India Company</a></td>
      <td>The East India Company (EIC) was an English, and later British, joint-stock company founded in 1600. It was formed to trade in the Indian Ocean region, initially with the East Indies (the Indian subcontinent and Southeast Asia), and later with East Asia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Pokémon_Company">The Pokémon Company</a></td>
      <td>The Pokémon Company (株式会社ポケモン, Kabushiki gaisha Pokémon) is a Japanese company responsible for brand management, production, publishing, marketing and licensing of the Pokémon franchise, which consists of video game software, a trading card game, anime television series, films, manga, home entertainment products, merchandise, and other ventures. It was established through a joint investment by the three businesses holding the copyright of Pokémon: Nintendo, Game Freak, and Creatures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Weather_Company">The Weather Company</a></td>
      <td>The Weather Company is a weather forecasting and information technology company that owns and operates weather.com and Weather Underground. The Weather Company has been a subsidiary of the Watson &amp; Cloud Platform business unit of IBM since 2016.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Honest_Company">The Honest Company</a></td>
      <td>The Honest Company, Inc. is an American consumer goods company, founded by actress Jessica Alba.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Longaberger_Company">The Longaberger Company</a></td>
      <td>The Longaberger Company is an American manufacturer and distributor of handcrafted maple wood baskets and other home and lifestyle products. The company opened in 1973, was acquired in 2013 by CVSL, Inc., and closed in 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Decimal_separator">Decimal separator</a></td>
      <td>A decimal separator is a symbol used to separate the integer part from the fractional part of a number written in decimal form (e.g., "." in 12.45). Different countries officially designate different symbols for use as the separator.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Thousands_on_a_Raft">Thousands on a Raft</a></td>
      <td>Thousands On A Raft is the second album by Pete Brown and Piblokto!, released in 1970 on Harvest Records.\n\n\n== Background ==\nThe album was the second one on which Brown and guitarist Jim Mullen collaborated.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2000s">2000s</a></td>
      <td>The 2010s (pronounced ''twenty-tens"; shortened to "the '10s", also known as the tens or the teens) was a decade that began on  January 1, 2010, and ended on  December 31, 2019.\nThe decade began amid a global financial crisis and subsequent international recession dating from the late 2000s.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hebrew_numerals">Hebrew numerals</a></td>
      <td>The system of Hebrew numerals is a quasi-decimal alphabetic numeral system using the letters of the Hebrew alphabet.\nThe system was adapted from that of the Greek numerals in the late 2nd century BCE.\nThe current numeral system is also known as the Hebrew alphabetic numerals to contrast with earlier systems of writing numerals used in classical antiquity.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/One_Thousand_and_One_Nights">One Thousand and One Nights</a></td>
      <td>One Thousand and One Nights (Arabic: أَلْفُ لَيْلَةٍ وَلَيْلَةٌ, ʾAlf Laylah wa-Laylah) is a collection of Middle Eastern folk tales compiled in Arabic during the Islamic Golden Age. It is often known in English as the Arabian Nights, from the first English-language edition (c. 1706–1721), which rendered the title as The Arabian Nights' Entertainment.The work was collected over many centuries by various authors, translators, and scholars across West, Central and South Asia, and North Africa.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Greater_London_Built-up_Area">Greater London Built-up Area</a></td>
      <td>The Greater London Built-up Area, or Greater London Urban Area, is a conurbation in south-east England that constitutes the continuous urban sprawl of London, and includes surrounding adjacent urban towns as defined by the Office for National Statistics. It is the largest urban area in the United Kingdom with a population of 9,787,426 in 2011.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/A_Thousand_Splendid_Suns">A Thousand Splendid Suns</a></td>
      <td>A Thousand Splendid Suns is a 2007 novel by Afghan-American author Khaled Hosseini, following the huge success of his bestselling 2003 debut The Kite Runner. Mariam, an illegitimate teenager from Herat, is forced to marry a shoemaker from Kabul after a family tragedy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/James_M._Cavanaugh">James M. Cavanaugh</a></td>
      <td>James Michael Cavanaugh (July 4, 1823 – October 30, 1879) was a U.S. Representative from Minnesota and a delegate from the Territory of Montana. He was born in Springfield, Massachusetts, July 4, 1823 and received an academic education.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Skathi_(moon)">Skathi (moon)</a></td>
      <td>Skathi , also named Saturn XXVII and originally spelled Skadi, is a natural satellite of the planet Saturn. Skathi is one of Saturn's irregular moons, in its Norse group of satellites.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_countries_by_past_and_projected_future_population">List of countries by past and projected future population</a></td>
      <td>\n== Introduction ==\nAll the figures shown here have been sourced from the International Data Base (IDB) Division of the United States Census Bureau. Every individual value has been rounded to the nearest thousand, to assure data coherence, particularly when adding up (sub)totals.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_figures">Significant figures</a></td>
      <td>Significant figures (also known as the significant digits, precision or resolution) of a number in positional notation are digits in the number that are reliable and necessary to indicate the quantity of something.\nIf a number expressing the result of a measurement (e.g., length, pressure, volume, or mass) has more digits than the number of digits allowed by the measurement resolution, then only as many digits as allowed by the measurement resolution are reliable, and so only these can be significant figures.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>CAMBREX CORP    ITEM 1A RISK FACTORS    FACTORS THAT MAY AFFECT FUTURE RESULTS         The <font color="blue">following risk factors</font> and other information included in this Annual  Report on Form 10-K should be <font color="blue">carefully</font> considered</td>
    </tr>
    <tr>
      <td>If any of the following  risks occur, the Companyapstas business, <font color="blue">financial condition</font>, operating results and  <font color="blue"><font color="blue">cash flows</font> could</font> be <font color="blue"><font color="blue">materially</font> <font color="blue">adversely</font> effected</font></td>
    </tr>
    <tr>
      <td>The risks and <font color="blue">uncertainties</font>  described below are not the only ones <font color="blue">the Company </font>faces</td>
    </tr>
    <tr>
      <td>Additionally, risks and  <font color="blue">uncertainties</font> not <font color="blue">presently known</font> to <font color="blue">the Company </font>or that it currently deems  immaterial also may impair its business, <font color="blue">financial condition</font>, operating results  and <font color="blue">cash flows</font> in the future</td>
    </tr>
    <tr>
      <td><font color="blue">THE COMPANY </font>&amp;apos S ANALYSIS, CONSIDERATION AND IMPLEMENTATION OF STRATEGIC  ALTERNATIVES MAY MATERIALLY ADVERSELY AFFECT OUR BUSINESS, FINANCIAL CONDITION  OR RESULTS OF OPERATIONS         As <font color="blue">previously</font> announced, <font color="blue">the Company </font>has retained Bear Stearns &amp; Co, Inc</td>
    </tr>
    <tr>
      <td>to act <font color="blue">as advisors</font> to the <font color="blue">Board of Directors </font>in the analysis and <font color="blue">consideration</font>  of <font color="blue">strategic <font color="blue">alternatives</font></font> to <font color="blue">maximize shareholder value</font>, including the potential  sale of <font color="blue">certain assets</font></td>
    </tr>
    <tr>
      <td>There are several <font color="blue">strategic <font color="blue">alternatives</font></font> that may be  pursued</td>
    </tr>
    <tr>
      <td>- ---------------  (dollars in thousands, except share data)                                          8  <PAGE>    However, we are <font color="blue">presently unable</font> to assess what impact any <font color="blue">particular strategic</font>  <font color="blue">alternative will</font> have on our stock price if accomplished, and our <font color="blue">consideration</font>  and <font color="blue">implementation</font> of <font color="blue">strategic <font color="blue">alternatives</font></font> may not be successful</td>
    </tr>
    <tr>
      <td><font color="blue">Uncertainties </font>and risks relating to our analysis and <font color="blue">consideration</font> of strategic  <font color="blue">alternatives</font> include but are not limited to:         - the analysis and <font color="blue">consideration</font> of <font color="blue">strategic <font color="blue">alternatives</font></font> may disrupt         <font color="blue">operations</font> and distract members of <font color="blue">management</font> and other employees, which         <font color="blue">could <font color="blue">adversely</font> affect</font> our results of <font color="blue">operations</font>;         - the process of exploring <font color="blue">strategic <font color="blue">alternatives</font></font> may be more time         consuming and <font color="blue">expensive than currently</font> anticipated;         - we may not be able to <font color="blue">successfully</font> achieve the benefits of the strategic         <font color="blue">alternative undertaken</font>; and         - perceived <font color="blue">uncertainties</font> as to the <font color="blue">future direction</font> of <font color="blue">the Company </font>may         result in the loss of employees, customers, clients or business partners</td>
    </tr>
    <tr>
      <td>WE MAY PURSUE TRANSACTIONS THAT MAY CAUSE US TO EXPERIENCE SIGNIFICANT CHARGES  TO EARNINGS THAT MAY ADVERSELY AFFECT OUR STOCK PRICE AND FINANCIAL CONDITION         We <font color="blue">regularly review potential <font color="blue"><font color="blue">transaction</font>s</font></font> related to <font color="blue">technologies</font>,  products, product rights and <font color="blue">businesses</font> complementary to our business</td>
    </tr>
    <tr>
      <td>These  <font color="blue"><font color="blue"><font color="blue">transaction</font>s</font> could</font> include mergers, <font color="blue">acquisition</font>s, <font color="blue">divestiture</font>s, strategic  alliances or <font color="blue">licensing <font color="blue">agreements</font></font></td>
    </tr>
    <tr>
      <td>In the future, we may choose to enter into  these <font color="blue"><font color="blue">transaction</font>s</font> at any time</td>
    </tr>
    <tr>
      <td>As a result of acquiring <font color="blue">businesses</font> or entering  into other <font color="blue">significant</font> <font color="blue"><font color="blue">transaction</font>s</font>, we have <font color="blue">previously</font> experienced, and may  continue to experience, <font color="blue">significant</font> charges to earnings for merger and related  expenses that may include <font color="blue">transaction</font> costs, closure costs or costs related to  the write-off of acquired in-process research and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>These costs may  also include substantial fees for <font color="blue">investment</font> bankers, attorneys, accountants,  financial printing costs, severance and other <font color="blue">closure costs associated with</font> the  <font color="blue">elimination</font> of duplicate or <font color="blue">discontinue</font>d products, employees, <font color="blue">operations</font> and  <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>Although we do not expect these charges to have a material adverse  effect upon our overall <font color="blue">financial condition</font>, these <font color="blue">charges could</font> have a material  <font color="blue">impact on</font> our results of <font color="blue">operations</font> for <font color="blue">particular quarters</font> or years and they  <font color="blue">could possibly</font> have an <font color="blue">adverse impact upon</font> the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>IF WE MAKE ACQUISITIONS, WE MAY EXPERIENCE DIFFICULTY INTEGRATING THE BUSINESSES  WHICH COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL CONDITION  AND RESULTS OF OPERATIONS         An important part of our business <font color="blue">growth strategy</font> is to acquire products,  product lines, <font color="blue">technologies</font> and <font color="blue">capabilities</font>, including through the <font color="blue">acquisition</font>  of <font color="blue">businesses</font> and to enhance the Companyapstas position in its <font color="blue">niche markets</font></td>
    </tr>
    <tr>
      <td>We  <font color="blue"><font color="blue">continually</font> explore</font> and <font color="blue">conduct discussions with</font> many <font color="blue">third parties</font> regarding  possible <font color="blue">acquisition</font>s</td>
    </tr>
    <tr>
      <td>Our ability to continue to achieve our <font color="blue">goals may depend</font>  upon our ability to effectively integrate such <font color="blue">businesses</font>, to achieve cost  <font color="blue">efficiencies</font> and to manage these <font color="blue">businesses</font> as part of our company</td>
    </tr>
    <tr>
      <td>However, we  may experience <font color="blue"><font color="blue">difficult</font>y integrating</font> the <font color="blue">merged companies <font color="blue">which could</font></font> have a  material adverse effect on the operating results or <font color="blue">financial condition</font> of the  <font color="blue">combined company</font></td>
    </tr>
    <tr>
      <td>As a result of <font color="blue">uncertainty</font> following an <font color="blue">acquisition</font> and during  the <font color="blue">integration</font> process, we could experience <font color="blue">disruption</font> in our business or  employee base</td>
    </tr>
    <tr>
      <td>There is also a risk that <font color="blue">key employees</font> of the <font color="blue">combined company</font>  <font color="blue">may seek employment elsewhere</font>, including <font color="blue">with <font color="blue">competitor</font>s</font>, or that valued  <font color="blue">employees may</font> be lost upon the <font color="blue">elimination</font> of <font color="blue">duplicate functions</font></td>
    </tr>
    <tr>
      <td>If we are not  able to <font color="blue">successfully</font> blend our products and <font color="blue">technologies</font> with the acquired  business to create the <font color="blue">advantages</font> the <font color="blue">acquisition</font> was intended to create, it may  effect our results of <font color="blue">operations</font>, our ability to develop and <font color="blue">introduce new</font>  products and the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Furthermore, there may be  <font color="blue">overlap between</font> our products, services or customers, and the <font color="blue">combined company</font>  may create conflicts in <font color="blue">relationships</font> or other <font color="blue"><font color="blue">commitment</font>s detrimental</font> to the  integrated <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>- ---------------  (dollars in thousands, except share data)                                          9  <PAGE>    IF WE FAIL TO IMPROVE THE OPERATIONS OF FUTURE ACQUIRED BUSINESSES, WE MAY BE  UNABLE TO ACHIEVE OUR GROWTH STRATEGY         Some of the <font color="blue">businesses</font> we have acquired or will acquire had or may have  <font color="blue">significant</font>ly lower operating <font color="blue">margins than</font> we do and/or operating <font color="blue">losses prior</font>  to the time we acquired them</td>
    </tr>
    <tr>
      <td>In the past, we have <font color="blue">occasionally</font> experienced  temporary delays in improving the operating margins of these acquired  <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>In the future, if we are unable to improve the operating margins of  acquired <font color="blue">businesses</font> or operate them profitably, we may be unable to achieve our  <font color="blue">growth strategy</font></td>
    </tr>
    <tr>
      <td>PHARMACEUTICAL, BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MAY DISCONTINUE OR  DECREASE THEIR USAGE OF OUR SERVICES         We depend on <font color="blue">pharmaceutical</font>, bio<font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font> companies</font>  that use our services for a large portion of our revenues</td>
    </tr>
    <tr>
      <td>Although there has  been a <font color="blue">trend among</font> these companies to <font color="blue">outsource therapeutic production</font>  functions, this trend may not continue</td>
    </tr>
    <tr>
      <td>We have observed increasing pressure on  the part of our customers to <font color="blue">reduce spending</font>, including the use of our services,  as a result of <font color="blue">negative economic trends <font color="blue">generally</font></font> and in the <font color="blue">pharmaceutical</font>  industry</td>
    </tr>
    <tr>
      <td>If these <font color="blue">companies <font color="blue">discontinue</font></font> or decrease their usage of our  services, including as a result of an <font color="blue">economic slowdown</font> in the overall United  States or foreign economies, our revenues and earnings could be lower than we  expect and our revenues may decrease or not grow at historical rates</td>
    </tr>
    <tr>
      <td>COMPETITION IN THE LIFE SCIENCES RESEARCH MARKET, AND/OR A REDUCTION IN DEMAND  FOR OUR PRODUCTS, COULD REDUCE SALES         The markets for our products are <font color="blue">competitive</font> and <font color="blue">price sensitive</font></td>
    </tr>
    <tr>
      <td>Other  <font color="blue">life science suppliers</font> have <font color="blue">significant</font> financial, operational, sales and  <font color="blue">marketing resources</font>, and experience in research and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>These and other  <font color="blue">companies may</font> have developed or could in the future develop new <font color="blue">technologies</font>  that <font color="blue">would compete with</font> our products or render our <font color="blue">products obsolete</font></td>
    </tr>
    <tr>
      <td>If a  <font color="blue">competitor</font> develops superior <font color="blue">technology</font> or cost-effective <font color="blue">alternatives</font> to our  products or services, our business, operating results, and <font color="blue">financial condition</font>  could be seriously harmed</td>
    </tr>
    <tr>
      <td>In addition, demand for our <font color="blue">products may weaken due</font>  to reduction in research and <font color="blue">development</font> budgets, loss of <font color="blue">distributors</font> or other  factors, which would have an adverse effect on our <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>The markets for certain of our products are also subject to specific  <font color="blue">competitive</font> risks and can be highly price <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitor</font>s have  competed in the <font color="blue">past by lowering prices on certain products</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitor</font>s may  <font color="blue">lower prices on</font> these or other products in the future and we may, in certain  cases, respond by lowering our prices</td>
    </tr>
    <tr>
      <td>This <font color="blue">would reduce revenues</font> and profits</td>
    </tr>
    <tr>
      <td>Conversely, failure to anticipate and respond to <font color="blue">price competition may hurt</font> our  market share</td>
    </tr>
    <tr>
      <td>We believe that customers in our <font color="blue">markets display loyalty</font> to their initial  supplier of a <font color="blue">particular product</font></td>
    </tr>
    <tr>
      <td>Therefore, it may be <font color="blue">difficult</font> to generate  sales to <font color="blue">potential customers</font> who have purchased products from <font color="blue">competitor</font>s</td>
    </tr>
    <tr>
      <td>To  the extent we are unable to be the first to develop and supply <font color="blue">new products</font>, our  <font color="blue">competitive</font> position may suffer</td>
    </tr>
    <tr>
      <td>As a result, we must  <font color="blue">continually</font> replace our contracts with new contracts to sustain our revenue</td>
    </tr>
    <tr>
      <td>In  addition, many of our long-term contracts may be cancelled or <font color="blue">delayed by clients</font>  for any <font color="blue">reason upon</font> notice</td>
    </tr>
    <tr>
      <td><font color="blue">Contracts </font>may be terminated for a variety of  reasons, including <font color="blue">termination</font> of product <font color="blue">development</font>, failure of products to  satisfy safety <font color="blue">requirements</font>, unexpected or undesired results from use of the  product or the clientapstas decision to forego a <font color="blue">particular study</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">The Company </font> </font>currently has a long-term sales contract within the <font color="blue">Human Health </font>segment that  <font color="blue">accounts</font> for more than 10prca  - ---------------  (dollars in thousands, except share data)                                          10  <PAGE>    of segment sales that is scheduled to expire at the end of 2008</td>
    </tr>
    <tr>
      <td>There is no  guarantee that this <font color="blue">contract will</font> be renewed</td>
    </tr>
    <tr>
      <td>Our failure to obtain new  contracts or <font color="blue">renew contracts</font> or the <font color="blue">cancellation</font> or delay of <font color="blue">existing contracts</font>  could have a material adverse effect on our business, <font color="blue">financial condition</font> and  results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Furthermore, because our revenue is <font color="blue">primarily generated on</font> a  contract-by-contract or purchase order basis, our revenue is <font color="blue">difficult</font> to  predict and <font color="blue">contributes</font> to the <font color="blue">variability</font> of our financial results from period  to period</td>
    </tr>
    <tr>
      <td>In addition, we do not believe that a backlog of contracts is a  <font color="blue">meaningful indicator</font> of our <font color="blue">future revenue</font> because much of our revenue is  resulting from short-term contracts or <font color="blue">purchase orders</font> and these contracts can  often be terminated for many reasons</td>
    </tr>
    <tr>
      <td>THE BIOPHARMA BUSINESS SEGMENT HAS EXPERIENCED AND MAY CONTINUE TO EXPERIENCE  SIGNIFICANT VOLATILITY IN PROFITABILITY AND THERE ARE NO ASSURANCES THAT IT WILL  RETURN TO ITS HISTORIC PROFITABILITY LEVEL         The Companyapstas Biopharma segment provides process <font color="blue">development</font> and  <font color="blue"><font color="blue">manufacturing</font> services on</font> a <font color="blue">contract basis</font> to bio<font color="blue">pharmaceutical</font> companies</td>
    </tr>
    <tr>
      <td>This  business has a very high fixed <font color="blue">cost structure</font> and its customers are often  <font color="blue"><font color="blue">dependent</font> on</font> the <font color="blue">availability</font> of funding and <font color="blue">pursuing drugs</font> that are in earlier  stages of <font color="blue">clinical trials</font>, and thus have <font color="blue">high failure rates</font></td>
    </tr>
    <tr>
      <td>Losses of one or  more customers can result in <font color="blue">significant</font> swings in <font color="blue">profitability</font> from quarter to  quarter and year to year</td>
    </tr>
    <tr>
      <td><font color="blue">Returning </font>to historic <font color="blue">profitability</font> levels is  <font color="blue"><font color="blue">dependent</font> on</font> <font color="blue">the Company </font>generating <font color="blue">significant</font> <font color="blue">additional</font> <font color="blue">revenues from</font>  existing and new customers, which can not be assured</td>
    </tr>
    <tr>
      <td><font color="blue">THE COMPANY </font>COULD BE SUBJECT TO ADDITIONAL IMPAIRMENT CHARGES IN THE FUTURE         During 2004 and 2005, <font color="blue">the Company </font><font color="blue">recorded <font color="blue">impairment charges</font></font> to reduce  goodwill and long-lived assets in 2005</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>may be subject to <font color="blue">additional</font>  <font color="blue">impairment charges</font> if the business units do not perform at or near projected  levels in the future</td>
    </tr>
    <tr>
      <td>Should the profit forecast for these <font color="blue">businesses</font> be revised  <font color="blue">significant</font>ly downward, <font color="blue">the Company </font>may incur <font color="blue">additional</font> <font color="blue">impairment charges</font></td>
    </tr>
    <tr>
      <td>OUR OPERATING RESULTS MAY UNEXPECTEDLY FLUCTUATE IN FUTURE PERIODS         The Companyapstas revenue and operating results have fluctuated, and could  continue to fluctuate, on a <font color="blue">quarterly basis</font></td>
    </tr>
    <tr>
      <td>The operating results for a  <font color="blue">particular quarter may</font> be lower than expected as a result of a number of  factors, including the timing of contracts; the delay or <font color="blue">cancellation</font> of a  contract; the mix of services provided; seasonal slowdowns in <font color="blue">different parts</font> of  the world; the timing of start-up expenses for <font color="blue">new services</font> and <font color="blue">facilities</font>; and  changes in <font color="blue"><font color="blue">government regulation</font>s</font></td>
    </tr>
    <tr>
      <td>Because a high percentage of the Companyapstas  costs are <font color="blue">relatively</font> fixed in the short term (such as the cost of maintaining  <font color="blue">facilities</font> and <font color="blue">compensating employees</font>), any one of these <font color="blue">factors could</font> have a  <font color="blue">significant</font> <font color="blue">impact on</font> the Companyapstas quarterly results</td>
    </tr>
    <tr>
      <td>In some quarters, the  Companyapstas revenue and operating results may fall below the <font color="blue">expectations</font> of  <font color="blue">securities analysts</font> and <font color="blue">investors due</font> to any of the <font color="blue">factors described</font> above</td>
    </tr>
    <tr>
      <td>In  such event, the <font color="blue">trading price</font> of the Companyapstas <font color="blue">common stock</font> would likely  decline, even if the decline in revenue did not have any long-term adverse  <font color="blue">implications</font> for the Companyapstas business</td>
    </tr>
    <tr>
      <td>OUR MARKET SHARE DEPENDS ON NEW PRODUCT INTRODUCTIONS AND ACCEPTANCE         Rapid <font color="blue">technological</font> change and <font color="blue">frequent new product <font color="blue">introduction</font>s</font> are  typical of the market for certain of our products and services</td>
    </tr>
    <tr>
      <td>Our future  <font color="blue">success will depend</font> in part on continuous, timely <font color="blue">development</font> and <font color="blue">introduction</font>  of <font color="blue">new products</font> that <font color="blue">address evolving market <font color="blue">requirements</font></font> and are attractive to  customers</td>
    </tr>
    <tr>
      <td>We believe successful new product <font color="blue">introduction</font>s provide a <font color="blue">significant</font>  <font color="blue">competitive</font> advantage because customers make an <font color="blue">investment</font> of time in selecting  and learning to use a new product, and are reluctant to <font color="blue">switch thereafter</font></td>
    </tr>
    <tr>
      <td>We  spend <font color="blue">significant</font> resources on internal research and <font color="blue">development</font>, as well as on  <font color="blue">technology</font> <font color="blue">development</font> elsewhere to support our effort to develop and introduce  <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>To the extent that we fail to <font color="blue">introduce new</font> and innovative  products, we could fail to obtain an adequate return on these <font color="blue">investment</font>s and  could lose market share to our <font color="blue">competitor</font>s, which may be <font color="blue">difficult</font> to regain</td>
    </tr>
    <tr>
      <td>An  <font color="blue">inability</font>, for <font color="blue">technological</font> or    - ---------------  (dollars in thousands, except share data)                                          11  <PAGE>    other reasons, to develop <font color="blue">successfully</font> and <font color="blue">introduce new</font> products could reduce  our growth rate or otherwise damage our business</td>
    </tr>
    <tr>
      <td>In the past, we have experienced, and may experience in the future, delays  in the <font color="blue">development</font> and <font color="blue">introduction</font> of products</td>
    </tr>
    <tr>
      <td>We cannot be assured that we  will keep pace with the rapid change in <font color="blue">life sciences research</font>, or that our new  <font color="blue">products will adequately meet</font> the <font color="blue">requirements</font> of the marketplace or achieve  <font color="blue">market acceptance</font></td>
    </tr>
    <tr>
      <td>Some of the factors effecting <font color="blue">market acceptance</font> of our  products include:         - <font color="blue">availability</font>, quality and <font color="blue">price as compared</font> to <font color="blue">competitive</font> products;         - the <font color="blue">functionality</font> of new and <font color="blue">existing products</font>;         - the timing of <font color="blue">introduction</font> of our <font color="blue">products as compared</font> to <font color="blue">competitive</font>         products;         - scientists &amp;apos  and customers &amp;apos  opinions of the productapstas utility and our         ability to <font color="blue">incorporate</font> their <font color="blue">feedback into future products</font>;         - <font color="blue">general trends</font> in <font color="blue">life sciences research</font></td>
    </tr>
    <tr>
      <td>The expenses or losses associated with unsuccessful product <font color="blue">development</font>  <font color="blue">activities</font> or lack of <font color="blue">market acceptance</font> of our <font color="blue">new products</font> could <font color="blue">adversely</font>  effect our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>FAILURE TO OBTAIN PRODUCTS AND COMPONENTS FROM THIRD-PARTY MANUFACTURERS COULD  EFFECT OUR ABILITY TO MANUFACTURE AND DELIVER OUR PRODUCTS         We rely on third-party <font color="blue">manufacture</font>rs to supply many of our <font color="blue">raw materials</font>,  <font color="blue">product <font color="blue">components</font></font>, and in some cases, entire products</td>
    </tr>
    <tr>
      <td>In addition, we have a  <font color="blue">single source</font> for supplies of some <font color="blue">raw materials</font> and <font color="blue">components</font> to our products</td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturing </font><font color="blue">problems may</font> occur with these and other <font color="blue">outside sources</font></td>
    </tr>
    <tr>
      <td>If such  problems occur, we <font color="blue">cannot ensure</font> that we will be able to <font color="blue">manufacture</font> our  <font color="blue">products profitably</font> or on time</td>
    </tr>
    <tr>
      <td>ANY SIGNIFICANT REDUCTION IN GOVERNMENT REGULATION OF THE DRUG DEVELOPMENT  PROCESS COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL  CONDITION AND RESULTS OF OPERATIONS         The design, <font color="blue">development</font>, testing, <font color="blue">manufacturing</font> and marketing of  bio<font color="blue">technology</font> and <font color="blue">pharmaceutical</font> products are subject to extensive <font color="blue">regulation by</font>  <font color="blue">governmental <font color="blue">authorities</font></font>, including the FDA and comparable <font color="blue">regulatory</font>  <font color="blue">authorities</font> in other countries</td>
    </tr>
    <tr>
      <td>The Companyapstas business depends in part on strict  <font color="blue">government regulation</font> of the drug <font color="blue">development</font> process</td>
    </tr>
    <tr>
      <td><font color="blue">Legislation </font>may be  introduced and <font color="blue">enacted from</font> time to time to <font color="blue">modify <font color="blue">regulations</font> administered by</font>  the FDA and governing the drug approval process</td>
    </tr>
    <tr>
      <td>Any <font color="blue">significant</font> reduction in  the scope of <font color="blue">regulatory</font> <font color="blue">requirements</font> or the <font color="blue">introduction</font> of <font color="blue">simplified drug</font>  <font color="blue">approval procedures could</font> have a material adverse effect on the Companyapstas  business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>VIOLATIONS OF CGMP AND OTHER GOVERNMENT REGULATIONS COULD HAVE A MATERIAL  ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL CONDITION AND RESULTS OF OPERATIONS         All <font color="blue">facilities</font> and <font color="blue">manufacturing</font> techniques used for <font color="blue">manufacturing</font> of  products for <font color="blue">clinical use</font> or for <font color="blue">commercial sale</font> in the <font color="blue">United States </font>must be  operated in <font color="blue">conformity with current</font> Good <font color="blue">Manufacturing </font>Practices ( &amp;quote cGMP &amp;quote )  <font color="blue"><font color="blue">regulations</font> as</font> required by the FDA The Companyapstas <font color="blue">facilities</font> are subject to  scheduled periodic <font color="blue">regulatory</font> and <font color="blue">customer inspections</font> to <font color="blue">ensure <font color="blue">compliance with</font></font>  cGMP and other <font color="blue">requirements</font> applicable to <font color="blue">such products</font></td>
    </tr>
    <tr>
      <td>A finding that the  Company had <font color="blue"><font color="blue">materially</font> violated</font> these <font color="blue">requirements</font> could result in <font color="blue">regulatory</font>  sanctions, the loss of a <font color="blue">customer contract</font>, the <font color="blue">disqualification</font> of data for  <font color="blue">client submissions</font> to <font color="blue">regulatory</font> <font color="blue">authorities</font> and/or a mandated closing of the  Companyapstas <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>Any such material <font color="blue">violations would</font> have a material adverse  effect on the Companyapstas business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The Securities and Exchange Commission ( &amp;quote SEC &amp;quote ) is <font color="blue">currently conducting</font> an  <font color="blue"><font color="blue">investigation</font> into</font> the Companyapstas inter-company accounting issue</td>
    </tr>
    <tr>
      <td>The  <font color="blue">investigation</font> began during the first half of 2003 after the    - ---------------  (dollars in thousands, except share data)                                          12  <PAGE>    Company <font color="blue">voluntarily</font> disclosed <font color="blue">certain matters</font> related to inter-company <font color="blue">accounts</font>  for the five-year period ending <font color="blue">December </font>31, 2001 that resulted in the  <font color="blue">restatement</font> of the Companyapstas <font color="blue">financial statements</font> for those years</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">The Company </font> </font>is <font color="blue">fully cooperating with</font> the SEC and does not expect further revisions to its  historical <font color="blue">financial statements</font> relating to these issues</td>
    </tr>
    <tr>
      <td>This <font color="blue">investigation</font>  could lead to an <font color="blue">adverse outcome</font> and <font color="blue">adversely</font> effect our business, financial  condition, results of <font color="blue">operations</font> and <font color="blue">cash flows</font></td>
    </tr>
    <tr>
      <td>LITIGATION MAY HARM OUR BUSINESS OR OTHERWISE NEGATIVELY IMPACT OUR MANAGEMENT  AND FINANCIAL RESOURCES         Substantial, complex or <font color="blue">extended <font color="blue">litigation</font> could</font> cause <font color="blue">the Company </font>to  incur large <font color="blue">expenditures</font> and distract our <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>For example, lawsuits by  employees, stockholders, counterparties to <font color="blue">acquisition</font> and <font color="blue">divestiture</font>  contracts, collaborators, <font color="blue">distributors</font>, customers, or end-users of our products  or <font color="blue">services could</font> be very costly and <font color="blue">substantially disrupt</font> our business</td>
    </tr>
    <tr>
      <td>Disputes from time to time <font color="blue">with such companies</font> or <font color="blue">individuals</font> are not uncommon,  and we <font color="blue">cannot assure</font> you that we <font color="blue">will always</font> be able to <font color="blue">resolve such disputes</font>  out of court or on terms favorable to the Company</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is involved in a number of lawsuits including a class action  <font color="blue">lawsuit filed against</font> Cambrex and certain current Company officers alleging the  failure to disclose in a <font color="blue">timely fashion</font> the <font color="blue">restatement</font> of results for the  five-year period ending <font color="blue">December </font>31, 2001 as discussed in the risk factor above,  as well as the loss of a <font color="blue">significant</font> contract at our <font color="blue">Baltimore </font><font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>If this  matter, or any of the Companyapstas other lawsuits, is resolved in an unfavorable  manner, they could have a material adverse effect on the operating results and  <font color="blue">cash flows</font> in <font color="blue"><font color="blue">future period</font>s</font></td>
    </tr>
    <tr>
      <td>LOSS OF KEY PERSONNEL COULD HURT OUR BUSINESS         <font color="blue">The Company </font><font color="blue">depends on</font> a number of <font color="blue">key executives</font></td>
    </tr>
    <tr>
      <td>The loss of services of  any of the Companyapstas <font color="blue">key executives</font> could have a material adverse effect on the  Companyapstas business</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>also <font color="blue">depends on</font> its ability to attract and retain qualified  scientific and <font color="blue">technical employees</font></td>
    </tr>
    <tr>
      <td>There can be no assurance <font color="blue">the Company </font>will  be able to retain its <font color="blue">existing scientific</font> and <font color="blue">technical employees</font>, or to attract  and retain <font color="blue">additional</font> qualified employees</td>
    </tr>
    <tr>
      <td>The Companyapstas <font color="blue">inability</font> to attract  and retain <font color="blue">qualified scientific</font> and <font color="blue">technical employees</font> would have a material  adverse effect on the Companyapstas business, <font color="blue">financial condition</font> and results of  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>POTENTIAL PRODUCT LIABILITY CLAIMS, ERRORS AND OMISSIONS CLAIMS IN CONNECTION  WITH SERVICES WE PERFORM AND POTENTIAL LIABILITY UNDER INDEMNIFICATION  AGREEMENTS BETWEEN US AND OUR OFFICERS AND DIRECTORS COULD ADVERSELY EFFECT OUR  EARNINGS AND FINANCIAL CONDITION         <font color="blue">The Company </font><font color="blue">manufacture</font>s products intended for use by the public</td>
    </tr>
    <tr>
      <td>In  addition, the Companyapstas services include the <font color="blue">manufacture</font> of <font color="blue">pharmaceutical</font> and  <font color="blue">biologic products</font> to be tested in human <font color="blue">clinical trials</font> and for <font color="blue">consumption by</font>  humans</td>
    </tr>
    <tr>
      <td>These <font color="blue">activities</font> could expose <font color="blue">the Company </font>to risk of <font color="blue">liability</font> for  personal injury or death to persons using <font color="blue">such products</font>, although <font color="blue">the Company </font> does not <font color="blue">presently market</font> or sell the products to end users</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>seeks  to reduce its potential <font color="blue">liability</font> through measures such as contractual  <font color="blue"><font color="blue">indemnification</font> provisions with clients</font> (the scope of which may vary from  client-to-client, and the <font color="blue">performances</font> of which are not secured), exclusion of  services requiring <font color="blue">diagnostic</font> or other <font color="blue">medical services</font>, and insurance  maintained by clients</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>could be <font color="blue">materially</font> and <font color="blue">adversely</font> effected if  it were required to pay damages or incur defense costs in <font color="blue">connection with</font> a  claim that is outside the scope of the <font color="blue"><font color="blue">indemnification</font> <font color="blue">agreements</font></font>, if the  <font color="blue">indemnity</font>, although applicable, is not performed in <font color="blue">accordance with</font> its terms or  if the Companyapstas <font color="blue">liability</font> exceeds the amount of <font color="blue">applicable insurance</font> or  <font color="blue">indemnity</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">the Company </font>could be held liable for errors and  omissions in <font color="blue">connection with</font> the services it performs</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>currently  maintains product <font color="blue">liability</font> and errors and <font color="blue">omissions insurance with respect</font> to  these risks</td>
    </tr>
    <tr>
      <td>There can be no assurance, however, that the Companyapstas insurance  <font color="blue">coverage will</font> be adequate or that insurance <font color="blue">coverage will</font> continue to be  <font color="blue">available on terms</font> acceptable to the Company</td>
    </tr>
    <tr>
      <td>- ---------------  (dollars in thousands, except share data)                                          13  <PAGE>         <font color="blue">The Company </font><font color="blue">also indemnifies</font> its officers and directors for <font color="blue">certain events</font>  or <font color="blue">occurrences while</font> the officer or director is, or was serving, at the  Companyapstas request in <font color="blue">such capacity</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">maximum potential amount</font> of future  payments <font color="blue">the Company </font>could be required to make under these <font color="blue">indemnification</font>  <font color="blue">agreements</font> is unlimited; however, <font color="blue">the Company </font>has a  &amp;quote <font color="blue">Director and Officer </font>&amp;quote   <font color="blue">insurance policy</font> that covers a portion of any <font color="blue">potential exposure</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">The Company </font> </font>could be <font color="blue">materially</font> and <font color="blue">adversely</font> effected if it were required to pay damages or  <font color="blue">incur legal costs</font> in <font color="blue">connection with</font> a claim above its <font color="blue">insurance limits</font></td>
    </tr>
    <tr>
      <td>ASSESSMENTS BY VARIOUS TAX AUTHORITIES MAY BE MATERIALLY DIFFERENT THAN WE HAVE  PROVIDED FOR AND WE MAY EXPERIENCE SIGNIFICANT VOLATILITY IN OUR ANNUAL AND  QUARTERLY EFFECTIVE TAX RATE         As a matter of course, <font color="blue">the Company </font>is <font color="blue">regularly audited by federal</font>, state,  and foreign tax <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>From time to time, these audits result in proposed  <font color="blue">assessments</font></td>
    </tr>
    <tr>
      <td>While <font color="blue">the Company </font>believes that it has <font color="blue">adequately provided</font> for any  such <font color="blue">assessments</font>, future settlements may be <font color="blue">materially</font> different than we have  provided for and <font color="blue">negatively</font> effect our earnings</td>
    </tr>
    <tr>
      <td>During 2005, the geographic shift of <font color="blue">forecasted income</font> resulted in the  recording of a <font color="blue">valuation allowance against</font> all <font color="blue">net domestic deferred tax assets</font></td>
    </tr>
    <tr>
      <td>Going forward, until such time as the Companyapstas domestic <font color="blue">profitability</font> is  restored and considered by <font color="blue">management</font> to be sustainable for the foreseeable  future, <font color="blue">the Company </font>will not record the <font color="blue">income tax benefit</font> or expense for  domestic pre-tax losses and <font color="blue">income respectively</font>, and <font color="blue">as such may</font> experience  <font color="blue">significant</font> <font color="blue">volatility</font> in its <font color="blue">effective tax rate</font></td>
    </tr>
    <tr>
      <td>At <font color="blue">December </font>31, 2005 the  Company has recorded a <font color="blue">valuation allowance against</font> domestic indefinite lived  <font color="blue">intangible deferred tax assets</font> of dlra16cmam926, because <font color="blue">the Company </font><font color="blue">could no longer</font>  preserve the <font color="blue">utilization</font> of <font color="blue">certain tax</font> planning strategies</td>
    </tr>
    <tr>
      <td>WE HAVE A SIGNIFICANT AMOUNT OF DEBT THAT COULD ADVERSELY EFFECT OUR FINANCIAL  CONDITION         <font color="blue">The Company </font>has a dlra277cmam500 revolving credit <font color="blue">facility</font> of which dlra81cmam943 was  <font color="blue">outstanding at</font> <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">the Company </font>had <font color="blue">privately placed</font>  notes of dlra100cmam000 (repaid in January 2006 by drawing down our <font color="blue">existing revolving</font>  credit <font color="blue">facility</font>)</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">generate sufficient cash flow</font> or otherwise  obtain <font color="blue">funds necessary</font> to make required <font color="blue">payments on</font> the notes, including from  cash and <font color="blue">cash equivalents on hand</font>, we will be in <font color="blue">default under</font> the terms of the  loan <font color="blue">agreements</font> and <font color="blue">indentures under which</font> we have <font color="blue">outstanding debt securities</font></td>
    </tr>
    <tr>
      <td>Even if we are able to meet our debt service obligations, the amount of  debt we have could <font color="blue">adversely</font> effect us in a number of ways, including:         - limiting our ability to obtain any <font color="blue">necessary financing</font> in the future for         working capital, capital <font color="blue">expenditures</font>, debt service <font color="blue">requirements</font>, or         other purposes;         - limiting our <font color="blue">flexibility</font> in planning for, or reacting to, changes in our         business;         - <font color="blue">placing us at</font> a <font color="blue">competitive</font> disadvantage relative to our <font color="blue">competitor</font>s who         have <font color="blue">lower levels</font> of debt;         - making us more vulnerable to a downturn in our business or the economy         <font color="blue">generally</font>;         - requiring us to use a substantial portion of our cash to <font color="blue">pay principal</font>         and <font color="blue">interest on</font> our debt, instead of <font color="blue">contributing</font> those funds to other         <font color="blue">purposes such as</font> working capital and capital <font color="blue">expenditures</font></td>
    </tr>
    <tr>
      <td>INTERNATIONAL UNREST OR FOREIGN CURRENCY FLUCTUATIONS COULD ADVERSELY EFFECT OUR  RESULTS         Our <font color="blue">international</font> revenues, which include <font color="blue">revenues from</font> our non-US  <font color="blue">subsidiaries</font> and <font color="blue">export <font color="blue">sales from</font></font> the US, represented 62prca of our product  revenues in 2005 and 61prca of our <font color="blue">product revenues</font> in 2004</td>
    </tr>
    <tr>
      <td>We    - ---------------  (dollars in thousands, except share data)                                          14  <PAGE>    expect that <font color="blue"><font color="blue">international</font> revenues <font color="blue">will continue</font></font> to account for a <font color="blue">significant</font>  percentage of our revenues for the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>There are a number of risks arising from our <font color="blue">international</font> business,  including:         - foreign currencies we receive for <font color="blue">sales outside</font> the US could be subject         to <font color="blue">unfavorable <font color="blue">exchange rates</font> with</font> the US dollar and reduce the amount         of revenue that we recognize;         - the <font color="blue">possibility</font> that <font color="blue">unfriendly nations</font> or <font color="blue">groups could boycott</font> our         products;         - <font color="blue">general economic</font> and <font color="blue">political conditions</font> in the markets in which we         operate;         - potential increased costs associated with overlapping tax structures;         - more limited protection for <font color="blue">intellectual property rights</font> in some         countries;         - unexpected changes in <font color="blue">regulatory</font> <font color="blue">requirements</font>;         - the <font color="blue">difficult</font>ies of <font color="blue">compliance with</font> a wide variety of <font color="blue">foreign laws</font> and         <font color="blue">regulations</font>;         - longer <font color="blue">accounts</font> receivable cycles in <font color="blue">certain foreign countries</font>; and         - import and export licensing <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> portion of our business is conducted in currencies other than  the US dollar, which is our reporting currency</td>
    </tr>
    <tr>
      <td>We recognize <font color="blue">foreign currency</font>  gains or losses arising from our <font color="blue">operations</font> in the <font color="blue">period incurred</font></td>
    </tr>
    <tr>
      <td>As a result,  currency <font color="blue">fluctuations</font> between the US dollar and the currencies in which we do  business have caused and <font color="blue">will continue</font> to cause <font color="blue">foreign currency</font> <font color="blue">transaction</font>  gains and losses</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> the effects of exchange rate <font color="blue">fluctuations</font>  upon our future operating results because of the number of <font color="blue">currencies involved</font>,  the <font color="blue">variability</font> of currency exposures, and the <font color="blue">potential <font color="blue">volatility</font></font> of currency  <font color="blue">exchange rates</font></td>
    </tr>
    <tr>
      <td>We engage in limited foreign exchange hedging <font color="blue"><font color="blue">transaction</font>s</font> to  manage our <font color="blue">foreign currency</font> exposure, but our strategies are short-term in  nature and may not <font color="blue">adequately protect</font> our operating results from the full  effects of exchange rate <font color="blue">fluctuations</font></td>
    </tr>
    <tr>
      <td>THE MARKET PRICE OF OUR STOCK COULD BE VOLATILE         The <font color="blue">market price</font> of our <font color="blue">common stock</font> has been subject to <font color="blue">volatility</font> and, in  the future, the <font color="blue">market price</font> of our <font color="blue">common stock</font> may fluctuate substantially due  to a variety of factors, including:         - quarterly <font color="blue">fluctuations</font> in our operating income and earnings per share         results;         - <font color="blue">technological</font> innovations or new product <font color="blue">introduction</font>s by us or our         <font color="blue">competitor</font>s;         - <font color="blue">economic conditions</font>;         - <font color="blue">disputes concerning patents</font> or <font color="blue">proprietary rights</font>;         - changes in earnings estimates and <font color="blue">market growth rate projections by</font>         <font color="blue">market research analysts</font>;         - sales of <font color="blue">common stock</font> by existing holders;         - loss of <font color="blue">key personnel</font>; and         - securities class actions or other <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> for our <font color="blue">common stock</font> may also be <font color="blue">effected by</font> our ability  to meet analysts &amp;apos  <font color="blue">expectations</font></td>
    </tr>
    <tr>
      <td>Any failure to meet such <font color="blue">expectations</font>, even  slightly, could have an adverse effect on the <font color="blue">market price</font> of our    - ---------------  (dollars in thousands, except share data)                                          15  <PAGE>    <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">stock market</font> is subject to <font color="blue">extreme price</font> and  volume <font color="blue">fluctuations</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">volatility</font> has had a <font color="blue">significant</font> effect on the market  prices of <font color="blue">securities issued by</font> many companies for <font color="blue">reasons unrelated</font> to the  operating performance of these companies</td>
    </tr>
    <tr>
      <td>INCIDENTS RELATED TO HAZARDOUS MATERIALS COULD ADVERSELY EFFECT OUR BUSINESS         Portions of our <font color="blue">operations</font> require the controlled use of <font color="blue">hazardous</font>  materials</td>
    </tr>
    <tr>
      <td>Although we are diligent in designing and <font color="blue">implementing safety</font>  procedures to <font color="blue">comply with</font> the <font color="blue">standards prescribed by federal</font>, state, and local  <font color="blue">regulations</font>, the risk of <font color="blue">accidental contamination</font> of property or injury to  <font color="blue">individuals</font> from these <font color="blue">materials cannot</font> be <font color="blue"><font color="blue">completely</font> eliminated</font></td>
    </tr>
    <tr>
      <td>In the event  of such an incident, we could be liable for any damages that result, <font color="blue">which could</font>  <font color="blue">adversely</font> effect our business</td>
    </tr>
    <tr>
      <td>Additionally, any incident could partially or <font color="blue">completely</font> shut down our  research and <font color="blue">manufacturing</font> <font color="blue">facilities</font> and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">generate waste</font> that must be transported to approved storage, treatment  and disposal <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">transportation</font> and disposal of such waste are  required to <font color="blue">meet applicable</font> state and <font color="blue">federal statutes</font> and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>The  storage, treatment and disposal of <font color="blue">such waste potentially exposes us</font> to  <font color="blue">environment</font>al <font color="blue">liability</font> if, in the future, such <font color="blue">transportation</font> and disposal are  deemed to have violated such statues and/or <font color="blue">regulations</font> or if the storage,  treatment and disposal <font color="blue">facilities</font> are inadequate and are proved to have damaged  the <font color="blue">environment</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is <font color="blue">also party</font> to several <font color="blue">environment</font>al remediation  <font color="blue">investigation</font>s and cleanups and, <font color="blue">along with</font> other companies, has been named a   &amp;quote potential responsible party &amp;quote  for <font color="blue">certain waste disposal sites</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>has  also retained the <font color="blue">liabilities with respect</font> to certain pre-closing <font color="blue">environment</font>al  <font color="blue">matters associated with</font> the sale of the <font color="blue">Rutherford Chemicals </font>business</td>
    </tr>
    <tr>
      <td>After  reviewing information currently available, <font color="blue">management</font> believes any <font color="blue">amount paid</font>  in excess of <font color="blue">accrued liabilities will</font> not have a material effect on its  business, <font color="blue">financial condition</font> or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>However, these matters,  if resolved in a <font color="blue">manner different from</font> the estimates, could have a material  adverse effect on the <font color="blue">financial condition</font>, operating results and <font color="blue">cash flows</font> when  resolved in future reporting periods</td>
    </tr>
    <tr>
      <td>THE POSSIBILITY WE WILL BE UNABLE TO PROTECT OUR TECHNOLOGIES COULD EFFECT OUR  ABILITY TO COMPETE         Our <font color="blue">success depends</font> to a <font color="blue">significant</font> degree upon our ability to develop  <font color="blue">proprietary products</font> and <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>However, we cannot be assured that  <font color="blue">patents will</font> be <font color="blue">granted on</font> any of our <font color="blue">patent <font color="blue">application</font>s</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">also cannot</font> be  assured that the scope of any of our issued <font color="blue">patents will</font> be <font color="blue">sufficiently broad</font>  to <font color="blue">offer meaningful protection</font></td>
    </tr>
    <tr>
      <td>We only have <font color="blue">patents issued</font> in selected  countries</td>
    </tr>
    <tr>
      <td>Therefore, <font color="blue">third parties</font> can make, use, and <font color="blue">sell products covered by</font>  our patents in any country in which we do not have <font color="blue">patent protection</font></td>
    </tr>
    <tr>
      <td>In  addition, our <font color="blue">issued patents</font> or patents we <font color="blue">license could</font> be <font color="blue">successfully</font>  challenged, invalidated or <font color="blue">circumvented</font> so that our <font color="blue">patent rights would</font> not  create an effective <font color="blue">competitive</font> barrier</td>
    </tr>
    <tr>
      <td>We provide our customers the right to  use our <font color="blue">products under label licenses</font> that are for <font color="blue">research purposes only</font></td>
    </tr>
    <tr>
      <td>These  <font color="blue">licenses could</font> be contested, and we cannot be assured that we <font color="blue">would either</font> be  aware of an <font color="blue">unauthorized use</font> or be able to enforce the <font color="blue">restrictions</font> in a  cost-effective manner</td>
    </tr>
    <tr>
      <td>If a third party claimed an intellectual property right to <font color="blue">technology</font> we  use, we may need to <font color="blue">discontinue</font> an important product or product line, alter our  products and processes, defend our right to use such <font color="blue">technology</font> in court or pay  license fees</td>
    </tr>
    <tr>
      <td>Although we may, under these circumstances, attempt to obtain a  license to <font color="blue">such intellectual property</font>, we may not be able to do so on favorable  terms, or at all</td>
    </tr>
    <tr>
      <td>Additionally, if our products are found to <font color="blue">infringe on</font> a third  partyapstas intellectual property, we may be required to pay damages for past  <font color="blue">infringement</font>, and lose the ability to <font color="blue">sell certain products</font> or receive licensing  revenues</td>
    </tr>
    <tr>
      <td>- ---------------  (dollars in thousands, except share data)                                          16  <PAGE>    COMPLIANCE WITH CHANGING REGULATION OF CORPORATE GOVERNANCE AND PUBLIC  DISCLOSURE MAY RESULT IN ADDITIONAL EXPENSE         Changing laws, <font color="blue">regulations</font> and standards relating to <font color="blue">corporate governance</font>  and <font color="blue">public <font color="blue">disclosure</font></font>, including the Sarbanes-Oxley Act of 2002, are creating  <font color="blue">uncertainty</font> for companies</td>
    </tr>
    <tr>
      <td>These new or changed laws and standards are subject  to <font color="blue">multiple interpretations</font>, in many <font color="blue">cases due</font> to their lack of <font color="blue">specification</font></td>
    </tr>
    <tr>
      <td>As a result, their <font color="blue">application</font> in practice may evolve over time as new guidance  is provided by <font color="blue">regulatory</font> and governing bodies <font color="blue">which could</font> result in higher  costs <font color="blue">necessitated</font> by revisions to <font color="blue"><font color="blue">disclosure</font>s</font> and governance practices</td>
    </tr>
    <tr>
      <td>We are  committed to maintaining <font color="blue">high standards</font> of <font color="blue">corporate governance</font> and public  <font color="blue">disclosure</font></td>
    </tr>
    <tr>
      <td>As a result of the efforts to <font color="blue">comply with</font> the <font color="blue">evolving laws</font> and  <font color="blue">regulations</font> increased general and <font color="blue">administrative expenses</font> have been experienced  and are likely to continue</td>
    </tr>
    <tr>
      <td>In particular, our efforts to <font color="blue">comply with</font> <font color="blue">Section  </font>404 of the Sarbanes-Oxley Act of 2002, and the related <font color="blue">assessments</font> have required  <font color="blue">commitment</font> of <font color="blue">significant</font> internal and <font color="blue">external financial</font> and operational  resources</td>
    </tr>
    <tr>
      <td>EMPLOYEES         At <font color="blue">December </font>31, 2005, <font color="blue">the Company </font>had 2cmam041 employees worldwide (965 of  whom were from <font color="blue">international</font> <font color="blue">operations</font>) compared with 1cmam938 employees at  <font color="blue">December </font>31, 2004 and 1cmam861 at <font color="blue">December </font>31, 2003</td>
    </tr>
    <tr>
      <td>production, administration, scientific and  <font color="blue">technical employees</font> are <font color="blue">represented by various local</font> and <font color="blue">national unions</font></td>
    </tr>
    <tr>
      <td>The  Company believes its <font color="blue">labor relations</font> are satisfactory</td>
    </tr>
    <tr>
      <td>SEASONALITY         <font color="blue">The Company </font>experiences some <font color="blue">seasonality primarily due</font> to planned plant  <font color="blue">shutdowns by</font> <font color="blue">the Company </font>and certain customers in the <font color="blue">third quarter</font></td>
    </tr>
    <tr>
      <td><font color="blue">Operating  </font>results for any quarter, however, are not <font color="blue">necessarily indicative</font> of results for  any <font color="blue">future period</font></td>
    </tr>
    <tr>
      <td>In particular, as a result of <font color="blue">various factors such as</font>  <font color="blue">acquisition</font>s, plant shutdowns, and the timing of large <font color="blue">contract revenue streams</font>,  <font color="blue">the Company </font>believes that period-to-period comparisons of its operating results  should not be <font color="blue">relied upon as</font> an <font color="blue">indication</font> of <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td>EXPORT AND INTERNATIONAL SALES         <font color="blue">The Company </font><font color="blue">exports numerous products</font> to various areas, principally Western  Europe, Asia and Canada</td>
    </tr>
    <tr>
      <td>Export <font color="blue">sales from</font> the Companyapstas domestic <font color="blue">operations</font> in  2005, 2004 and 2003 amounted to dlra47cmam115, dlra29cmam945 and dlra22cmam100, respectively</td>
    </tr>
    <tr>
      <td>Sales from <font color="blue">international</font> <font color="blue">operations</font> were dlra234cmam199 in 2005, dlra238cmam673 in 2004, and  dlra223cmam666 in 2003</td>
    </tr>
    <tr>
      <td><font color="blue">Refer to Note </font>#17 to the Cambrex Corporation and Subsidiaries  Consolidated Financial Statements</td>
    </tr>
    <tr>
      <td>AVAILABLE INFORMATION         This annual report on Form 10-K, the Companyapstas quarterly reports on Form  10-Q, the Companyapstas current reports on Form 8-K, and <font color="blue">amendments</font> to those reports  filed or <font color="blue">furnished pursuant</font> to Section 13(a) or 15(d) of the Securities Exchange  Act of 1934, are made <font color="blue">available free</font> of charge on the Companyapstas Internet website  www</td>
    </tr>
    <tr>
      <td><font color="blue">com as soon as reasonably practicable</font> after such material is  <font color="blue">electronically <font color="blue">filed with</font></font> or furnished to the SEC The most recent  <font color="blue">certifications by</font> the Companyapstas Chief Executive Officer and Chief Financial  Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 are filed as  exhibits to this Annual report on Form 10-K Last year <font color="blue">the Company </font><font color="blue">filed with</font>  the New York Stock Exchange the Annual Chief Executive Officer Certification as  required by Section 303A12</td>
    </tr>
    <tr>
      <td>- ---------------  (dollars in thousands, except share data)                                          17  <PAGE>         Reports filed by <font color="blue">the Company </font>with the SEC may be read and <font color="blue">copied at</font> the  SECapstas <font color="blue">Public Reference Room </font>at 100 F Street, NE, Washington, DC 20549</td>
    </tr>
    <tr>
      <td><font color="blue">Information </font>on the operation of the <font color="blue">Public Reference Room </font>may be obtained by  calling the SEC at 1-800-SEC-0330</td>
    </tr>
    <tr>
      <td>gov that contains reports, proxy and information statements and other  information regarding issuers that <font color="blue">file electronically with</font> the SEC         The following <font color="blue">corporate governance</font> documents are <font color="blue">available free</font> of charge  on the Companyapstas website: the charters of our Audit, Regulatory Affairs,  Compensation and Governance Committees, our <font color="blue">Corporate Governance Guidelines </font>and  our <font color="blue">Code of Business Conduct and Ethics</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">corporate governance</font> documents  are <font color="blue">also available</font> in print to any <font color="blue">stockholder requesting</font> a copy from our  <font color="blue">corporate secretary at</font> our <font color="blue">principal executive offices</font></td>
    </tr>
    <tr>
      <td><font color="blue">Information </font><font color="blue">contained on</font>  our website is not part of this report</td>
    </tr>
    <tr>
      <td>We <font color="blue">will also post on</font> our website any  <font color="blue">amendments</font> to or waivers of our <font color="blue">Code of Business Conduct and Ethics</font> that relate  to our Chief Executive Officer, Chief Financial Officer and Principal Accounting  Officer</td>
    </tr>
  </tbody>
</table>